[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
June 2007

Systemic Adjuvant Therapy for Patients With High-Risk Melanoma

Arch Dermatol. 2007;143(6):779-782. doi:10.1001/archderm.143.6.779

Question: What is the evidence that systemic adjuvant therapy is of benefit in patients with high-risk resected melanoma? In their study, Verma et al include patients with thick melanomas (at least 4.0 mm in thickness), Clark level V tumor, primary melanoma with in-transit metastases, primary melanoma with clinically apparent lymph node involvement or a positive sentinel lymph node biopsy result, resected lymph node disease with no known primary site, and current American Joint Committee on Cancer (AJCC) 2002 stage IIB, IIC, and III disease.

First Page Preview View Large
First page PDF preview
First page PDF preview
×